Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
H.C. Wainwright Downgrades Fate Therapeutics (FATE) to Neutral
March 6, 2018 7:57 AM ESTH.C. Wainwright downgraded Fate Therapeutics (NASDAQ: FATE) from Buy to Neutral with a price target of $12.00 (from $7.00).
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $13.77 yesterday.
... MoreFate Therapeutics (FATE) Misses Q4 EPS by 5c
March 5, 2018 4:04 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.29), $0.05 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $940 thousand.
Cash, cash equivalents and short-term investments as of December 31, 2017 were $100.9 million compared to $92.1 million as of... More
